You are here: Industry Insights > IBS

News List

LBPs may offer hope to IBS patients in the near future, says report europeanpharmaceuticalreview
August 03, 2021
Live biotherapeutic products (LBPs) are expected to help patients with IBS who currently have no US- or EMA-approved treatments.
Deception is not necessary for the placebo effect, finds new study europeanpharmaceuticalreview
April 02, 2021
The study found that patients with irritable bowel syndrome taking open-label placebo reported similar improvements to those taking double-blind placebo.
Sanofi, Babylon link-up to tackle digestive health pharmatimes
March 06, 2020
Sanofi has teamed up with video consultation business Babylon, in order to offer an online AI Health Service for those who suffer from digestive health issues.
First Subject Dosed in Olorinab Trial for Abdominal Pain from IBS americanpharmaceuticalreview
July 26, 2019
rena Pharmaceuticals announced the first subject has been dosed in the Phase 2 CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2) in development for ...
Marketing OK'd for Device to Help Reduce IBS Symptoms in Adolescents drugs
June 12, 2019
Marketing OK'd for Device to Help Reduce IBS Symptoms in Adolescents.
Marketing OK'd for Device to Help Reduce IBS Symptoms in Adolescents drugs
June 11, 2019
Marketing OK'd for Device to Help Reduce IBS Symptoms in Adolescents.
Vitamin D supplements could ease painful IBS symptoms europeanpharmaceuticalreview
April 29, 2019
Researchers find that vitamin D supplements could help to ease painful Irritable Bowel Syndrome symptoms…
Sandoz announces results of digital innovation ‘HACk’ pharmaphorum
March 12, 2019
A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic in Uganda, were the three winners of Sandoz’s competition to improve access to healthcare using digital innovation.
Strong IBS and constipation Phase 3 data sends Ardelyx shares rocketing 60% pharmafile
October 13, 2017
Ardelyx has confirmed that its NHE3 inhibitor tenapanor met all its primary and secondary endpoints in the study of its treatment efficacy against irritable bowel syndrome and constipation (IBS-C).
New Bowel Disorder Treatments Needed, FDA Says drugs.com
April 18, 2017
There's no known cause or cure for irritable bowel syndrome (IBS), which affects more than 15 million Americans, according to the U.S. Food and Drug Administration.